NO20020467L - Purinderivatinhibitorer av tyrosinproteinkinase syk - Google Patents

Purinderivatinhibitorer av tyrosinproteinkinase syk

Info

Publication number
NO20020467L
NO20020467L NO20020467A NO20020467A NO20020467L NO 20020467 L NO20020467 L NO 20020467L NO 20020467 A NO20020467 A NO 20020467A NO 20020467 A NO20020467 A NO 20020467A NO 20020467 L NO20020467 L NO 20020467L
Authority
NO
Norway
Prior art keywords
ill
protein kinase
purine derivative
tyrosine protein
derivative inhibitors
Prior art date
Application number
NO20020467A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020467D0 (no
Inventor
Stephen Paul Collingwood
Judy Hayler
Darren Mark Le Grand
Henri Mattes
Keith Allan Menear
Clive Victor Walker
Xiao-Ling Cockcroft
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20020467D0 publication Critical patent/NO20020467D0/no
Publication of NO20020467L publication Critical patent/NO20020467L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20020467A 1999-07-30 2002-01-29 Purinderivatinhibitorer av tyrosinproteinkinase syk NO20020467L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9918035.8A GB9918035D0 (en) 1999-07-30 1999-07-30 Organic compounds
PCT/EP2000/007311 WO2001009134A1 (fr) 1999-07-30 2000-07-28 Inhibiteurs de derives de purine de la tyrosine kinase syk

Publications (2)

Publication Number Publication Date
NO20020467D0 NO20020467D0 (no) 2002-01-29
NO20020467L true NO20020467L (no) 2002-03-20

Family

ID=10858317

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020467A NO20020467L (no) 1999-07-30 2002-01-29 Purinderivatinhibitorer av tyrosinproteinkinase syk

Country Status (33)

Country Link
US (1) US6589950B1 (fr)
EP (1) EP1200435B1 (fr)
JP (2) JP2003506375A (fr)
KR (1) KR100485289B1 (fr)
CN (1) CN1213047C (fr)
AR (1) AR029175A1 (fr)
AT (1) ATE251160T1 (fr)
AU (1) AU767349B2 (fr)
BR (1) BR0012888A (fr)
CA (1) CA2379560C (fr)
CO (1) CO5180626A1 (fr)
CZ (1) CZ2002299A3 (fr)
DE (1) DE60005684T2 (fr)
DK (1) DK1200435T3 (fr)
EC (1) ECSP003589A (fr)
ES (1) ES2208395T3 (fr)
GB (1) GB9918035D0 (fr)
HK (1) HK1046679A1 (fr)
HU (1) HUP0201935A3 (fr)
IL (1) IL147455A0 (fr)
MX (1) MXPA02001102A (fr)
MY (1) MY126862A (fr)
NO (1) NO20020467L (fr)
NZ (1) NZ516667A (fr)
PE (1) PE20010543A1 (fr)
PL (1) PL354477A1 (fr)
PT (1) PT1200435E (fr)
RU (1) RU2248977C2 (fr)
SK (1) SK285730B6 (fr)
TR (1) TR200200234T2 (fr)
TW (2) TWI274754B (fr)
WO (1) WO2001009134A1 (fr)
ZA (1) ZA200200783B (fr)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1941501A (en) * 1999-11-30 2001-06-12 Parker Hughes Institute Syk localized at centrosome
FR2802091A1 (fr) * 1999-12-08 2001-06-15 Oreal Compositions pour la teinture des fibres keratiniques contenant des derives de paraphenylenediamine a groupement azetidinyle
AU2001293817A1 (en) 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
ES2324981T3 (es) 2000-12-21 2009-08-21 Smithkline Beecham Corporation Pirimidinaminas como moduladores de la angiogenesis.
GB0101686D0 (en) * 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
AU2002342051B2 (en) * 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
WO2003059913A1 (fr) * 2002-01-10 2003-07-24 Bayer Healthcare Ag Inhibiteurs de la rho-kinase
CA2473910C (fr) 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Derives de pyrimidine en tant qu'inhibiteurs de la rho-kinase
JP4469179B2 (ja) 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003212335B8 (en) * 2002-03-13 2009-04-23 Janssen Pharmaceutica N.V. Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
DK1485354T3 (da) 2002-03-13 2008-09-01 Janssen Pharmaceutica Nv Sulfonylamino-derivater som nye inhibitorer af histandeacetylase
US6897307B2 (en) 2002-03-28 2005-05-24 Novartis Ag Process for preparing 2,6-diaminopurine derivatives
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
AU2003276125B2 (en) * 2002-06-17 2007-05-17 Smithkline Beecham Corporation Chemical process
CN101423497A (zh) * 2002-07-19 2009-05-06 记忆药物公司 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑和4-氨基苯并呋喃化合物
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
EP1444982A1 (fr) * 2003-02-06 2004-08-11 Merckle Gmbh Utilisation des dérivés de purine comme inhibiteurs sélectifs de kinases
KR20120062863A (ko) 2003-07-30 2012-06-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물
CA2535620A1 (fr) * 2003-08-15 2005-02-24 Irm Llc Composes et compositions inhibiteurs de l'activite du recepteur tyrosine kinase
ATE500254T1 (de) * 2003-09-25 2011-03-15 Janssen Pharmaceutica Nv Die replikation von hiv hemmende purinderivate
ZA200603719B (en) * 2003-11-06 2007-09-26 Celgene Corp Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders
EP1682150B1 (fr) * 2003-11-10 2012-12-26 The Scripps Research Institute Compositions et procedes pour induire la dedifferenciation cellulaire
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
US8057815B2 (en) * 2004-04-19 2011-11-15 Portola Pharmaceuticals, Inc. Methods of treatment with Syk inhibitors
WO2005118543A1 (fr) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Inhibiteur des kinases et utilisation de cet inhibiteur
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
MX2007001127A (es) 2004-07-27 2007-07-11 Sgx Pharmaceuticals Inc Moduladores de pirrolo-piridina cinasa.
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
MX2007001126A (es) 2004-07-27 2007-09-25 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
WO2006010750A1 (fr) 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Derives d'indolyl alkyl amine substitues utilises en tant que nouveaux inhibiteurs d'histone deacetylase
EP1796679A1 (fr) * 2004-09-10 2007-06-20 Altana Pharma AG Combinaison de ciclesonide et d'inhibiteur de syk et procedes d'utilisation
CA2584295C (fr) 2004-11-24 2014-08-26 Rigel Pharmaceuticals, Inc. Composes de spiro-2, 4-pyrimidinediamine et leurs utilisations
CN100526315C (zh) * 2005-06-16 2009-08-12 浙江医药股份有限公司新昌制药厂 N2-喹啉或异喹啉取代的嘌呤衍生物及其制备方法和其用途
PE20070593A1 (es) * 2005-10-13 2007-07-23 Glaxo Group Ltd Compuestos pirrolopirimidina como inhibidores de syk
US7803806B2 (en) * 2005-11-03 2010-09-28 Sgx Pharmaceuticals, Inc. Pyrimidinyl-thiophene kinase modulators
WO2007070872A1 (fr) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Inhibiteurs de kinase et leurs utilisations
AU2007206942B2 (en) 2006-01-19 2012-08-23 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
SI1981874T1 (sl) * 2006-01-19 2009-10-31 Janssen Pharmaceutica Nv Aminofenilni derivati kot novi inhibitorji histon deacetilaze
JP5137849B2 (ja) * 2006-01-19 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
AU2007309149C1 (en) 2006-10-23 2013-04-04 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
EP2537830A1 (fr) 2006-12-08 2012-12-26 Irm Llc Composés et compositions en tant quýinhibiteurs de protéine kinase
BRPI0720264B1 (pt) * 2006-12-08 2022-03-03 Novartis Ag Compostos e composições como inibidores de proteína cinase
WO2008081928A1 (fr) * 2006-12-28 2008-07-10 Taisho Pharmaceutical Co., Ltd. Composé pyrazolopyridimidine
WO2008107444A1 (fr) 2007-03-07 2008-09-12 Boehringer Ingelheim International Gmbh Nouveaux composés
JP2010524858A (ja) 2007-04-10 2010-07-22 エスジーエックス ファーマシューティカルズ、インコーポレイテッド 縮合環複素環キナーゼ調節因子
CN101289449A (zh) * 2007-04-20 2008-10-22 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和应用
WO2008135232A1 (fr) * 2007-05-02 2008-11-13 Riccardo Cortese Utilisation et compositions de dérivés de purine pour le traitement de troubles prolifératifs
JP2010528991A (ja) * 2007-05-21 2010-08-26 エスジーエックス ファーマシューティカルズ、インコーポレイテッド 複素環式キナーゼ調節因子
CL2008001540A1 (es) * 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
US7705004B2 (en) 2007-08-17 2010-04-27 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
FR2929851B1 (fr) 2008-04-09 2012-11-30 Centre Nat Rech Scient Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
PT2323993E (pt) 2008-04-16 2015-10-12 Portola Pharm Inc 2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak
CN103224497A (zh) * 2008-04-22 2013-07-31 波托拉医药品公司 蛋白激酶抑制剂
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
HUE035029T2 (en) 2008-05-21 2018-03-28 Ariad Pharma Inc Kinase inhibitor phosphorus derivatives
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010111406A2 (fr) * 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Composés et leurs utilisations thérapeutiques
SG181803A1 (en) * 2009-12-17 2012-07-30 Merck Sharp & Dohme Aminopyrimidines as syk inhibitors
ES2545616T3 (es) 2009-12-23 2015-09-14 Takeda Pharmaceutical Company Limited Pirrolidinonas heteroaromáticas condensadas como inhibidores de SYK
WO2011153553A2 (fr) 2010-06-04 2011-12-08 The Regents Of The University Of California Méthodes et compositions pour l'inhibition de kinases
EP2489663A1 (fr) 2011-02-16 2012-08-22 Almirall, S.A. Composés en tant qu'inhibiteurs de la syk kinase
EA201391626A1 (ru) 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
WO2012154518A1 (fr) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Bipyridylaminopyridines en tant qu'inhibiteurs de syk
WO2012154520A1 (fr) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Pyridylaminopyridines en tant qu'inhibiteurs de syk
JP2014513686A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Ｓｙｋ阻害薬としてのアミノピリミジン
US9353115B2 (en) 2011-06-01 2016-05-31 Janus Biotherapeutics, Inc. Immune system modulators
EP2723739B1 (fr) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Dérivés de 6-aza-isoindolin-1-one substitués
EP2763974B1 (fr) 2011-10-05 2016-09-14 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un phényl carboxamide
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
AU2012340555B2 (en) 2011-11-23 2016-10-20 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
AR090650A1 (es) * 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
EP2863914B1 (fr) 2012-06-20 2018-10-03 Merck Sharp & Dohme Corp. Dérivés de pyrazolyle en tant qu'inhibiteurs de syk
EP2863913B1 (fr) 2012-06-20 2018-09-12 Merck Sharp & Dohme Corp. Analogues d'imidazolyle en tant qu'inhibiteurs de syk
WO2013192088A1 (fr) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase splénique (syk) diazines et triazines substituées
WO2013192098A1 (fr) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. Inhibiteurs à pyridine substituée de la tyrosine kinase de la rate (syk)
EP2884982B1 (fr) 2012-08-20 2017-09-20 Merck Sharp & Dohme Corp. Inhibiteurs de la phényle tyrosine kinase de la rate (syk) substitués
US9586931B2 (en) 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
EP2931281B1 (fr) 2012-12-12 2018-01-17 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase splénique contenant une aminopyridine
WO2014100314A1 (fr) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Aminopyridines substituées par thiazole en tant qu'inhibiteurs de la tyrosine kinase de la rate
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2014176216A1 (fr) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Aminopyrimidines substituées par thiazole utilisées en tant qu'inhibiteurs de tyrosine kinase splénique
EP2988744A4 (fr) 2013-04-26 2016-11-02 Merck Sharp & Dohme Composés aminohétéroaryle à substitution thiazole inhibiteurs de tyrosine kinase splénique
CN104418858B (zh) * 2013-08-30 2018-12-11 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
WO2015094997A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés aminohétéroaryle à substitution thiazole utilisés comme inhibiteurs de la tyrosine kinase splénique
WO2015095445A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés aminohétéroaryle à substitution thiazole utilisés comme inhibiteurs de la tyrosine kinase splénique
US9670196B2 (en) 2013-12-20 2017-06-06 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
WO2015138273A1 (fr) 2014-03-13 2015-09-17 Merck Sharp & Dohme Corp. Composés 2-pyrazine carboxamide utiles comme inhibiteurs de la tyrosine kinase splénique
EP3134405B1 (fr) 2014-04-25 2019-08-28 Pfizer Inc Composes hetero-aromatiques et leur utilisation comme ligands d1 de la dopamine
RU2570113C1 (ru) * 2014-12-08 2015-12-10 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук N-(2-ацетамидопурин-6-ил)глицин, обладающий противотуберкулезной активностью
WO2016130920A2 (fr) 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
RU2018106663A (ru) * 2015-07-24 2019-08-26 Глэксо Груп Лимитед Лечение витилиго
WO2017181285A1 (fr) 2016-04-21 2017-10-26 The Royal Institution For The Advancement Of Learning/Mcgill University Composés de purine et méthode pour le traitement du cancer
WO2018075937A1 (fr) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et leurs utilisations
BR112020007679A2 (pt) 2017-10-19 2020-10-20 Bayer Animal Health Gmbh uso de pirrolidonas heteroaromáticas fundidas para tratamento e prevenção de doenças em animais.
WO2019241896A1 (fr) * 2018-06-22 2019-12-26 The Royal Institution For The Advancement Of Learning/Mcgill University Composés de purine et procédé pour letraitement du cancer
WO2020123675A1 (fr) * 2018-12-11 2020-06-18 Duke University Compositions et procédés pour le traitement du cancer
EP3942045A1 (fr) 2019-03-21 2022-01-26 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
EP4054579A1 (fr) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529497A1 (de) 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US5583137A (en) * 1992-02-19 1996-12-10 Pfizer Inc. Heterocyclic compounds for enhancing antitumor activity
CZ236494A3 (en) 1992-04-03 1994-12-15 Upjohn Co Pharmaceutically active bicyclic-heterocyclic amines
US5550132A (en) 1994-06-22 1996-08-27 University Of North Carolina Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
EP0874846B1 (fr) * 1995-11-01 2003-04-02 Novartis AG Derives purines et procedes de preparation associes
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
AU735127B2 (en) 1997-08-07 2001-06-28 Regents Of The University Of California, The Purine inhibitor of protein kinases, G proteins and polymerases
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
TWI255268B (en) 2006-05-21
DK1200435T3 (da) 2004-02-02
KR20020015394A (ko) 2002-02-27
MY126862A (en) 2006-10-31
JP2003506375A (ja) 2003-02-18
RU2248977C2 (ru) 2005-03-27
CN1365360A (zh) 2002-08-21
CZ2002299A3 (cs) 2002-04-17
TR200200234T2 (tr) 2002-06-21
TW200524932A (en) 2005-08-01
HK1046679A1 (zh) 2003-01-24
MXPA02001102A (es) 2002-08-20
NO20020467D0 (no) 2002-01-29
WO2001009134A1 (fr) 2001-02-08
HUP0201935A3 (en) 2005-02-28
PL354477A1 (en) 2004-01-26
SK285730B6 (sk) 2007-07-06
BR0012888A (pt) 2002-04-09
CA2379560A1 (fr) 2001-02-08
AU767349B2 (en) 2003-11-06
HUP0201935A2 (hu) 2002-11-28
PE20010543A1 (es) 2001-05-14
EP1200435B1 (fr) 2003-10-01
ATE251160T1 (de) 2003-10-15
US6589950B1 (en) 2003-07-08
KR100485289B1 (ko) 2005-04-27
JP2007217426A (ja) 2007-08-30
CO5180626A1 (es) 2002-07-30
GB9918035D0 (en) 1999-09-29
PT1200435E (pt) 2004-02-27
CA2379560C (fr) 2009-09-29
TWI274754B (en) 2007-03-01
DE60005684T2 (de) 2004-07-29
SK1262002A3 (en) 2002-07-02
DE60005684D1 (de) 2003-11-06
IL147455A0 (en) 2002-08-14
CN1213047C (zh) 2005-08-03
EP1200435A1 (fr) 2002-05-02
AU6567700A (en) 2001-02-19
ZA200200783B (en) 2003-04-30
ECSP003589A (es) 2002-02-25
NZ516667A (en) 2004-05-28
AR029175A1 (es) 2003-06-18
ES2208395T3 (es) 2004-06-16

Similar Documents

Publication Publication Date Title
NO20020467L (no) Purinderivatinhibitorer av tyrosinproteinkinase syk
CY2008015I1 (el) Δικυκλικες ετepοαρωματικες ενωσεις σαν αναστολεις πρωτεϊνης κινασης τυροσινης
FR13C0003I2 (fr) Inhibiteurs cycliques de proteine tyrosine kinase
CY2014034I1 (el) Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
NO20021820D0 (no) Tyrosinkinaseinhibitorer
IL182428A0 (en) Indolylmaleimide derivatives as protein kinase c inhibitors
ATE255575T1 (de) Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren
NO20022864L (no) Aminotiazol inhibitorer av syklin uavhengig kinase
ATE430149T1 (de) Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
DE60117568D1 (de) Kondensierte pyrazol derivate als protein kinase inhibitoren
DE69511253D1 (de) Wasserlösliche 3-arylidene-2-oxindole derivate als tyrosine kinase inhibitoren
NO20021783D0 (no) Alkylamino-substituerte bicykliske nitrogen-heterocykler som inhibitorer for P38-protein-kinase
NO990123D0 (no) Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
ATE205836T1 (de) Bicyclische 4-aralkylaminopyrimidin-derivate als tyrosinkinase-inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application